Cystatin C: What Your Number Changes About Your Treatment

What Cystatin C Actually Measures

Cystatin C is a cysteine protease inhibitor encoded by the CST3 gene. Every nucleated cell produces it at a steady rate, it passes freely through the glomerular membrane, and the tubules neither secrete nor reabsorb meaningful amounts. That makes it a nearly perfect filtration marker. KDIGO 2012 defined eGFRcys as a confirmatory tool when creatinine-based eGFR is uncertain.

Why Creatinine Alone Falls Short

Serum creatinine reflects muscle breakdown. A 120 kg bodybuilder and a 55 kg sedentary woman can have identical creatinine values while their actual GFRs differ by 40 mL/min. Race-correction equations introduced further error. A 2021 NEJM study examining the CKD-EPI equation found that removing the race coefficient improved accuracy but still left a residual bias that cystatin C resolves because it is muscle-independent (NEJM 2021, Delgado et al.).

The CKD-EPI Cystatin C Equation

The 2021 CKD-EPI equation combining creatinine and cystatin C (CKD-EPI creatinine-cystatin C 2021) outperforms either marker alone. In a validation cohort of 5,352 participants, the combined equation cut the proportion of participants with GFR misclassified by more than 30% from 8.0% (creatinine only) to 4.7% (Inker et al., NEJM 2021). Your prescriber should be using this combined equation if your creatinine result looks inconsistent with your symptoms or body composition.

Normal Cystatin C Range and What Each Zone Means

The Reference Interval

Most certified labs report a normal cystatin C range of 0.62 to 1.15 mg/L in adults. The National Kidney Foundation notes that values increase modestly with age even in healthy adults, so a result of 1.05 mg/L in a 70-year-old may still reflect age-appropriate filtration (NKF/ASN Task Force, JASN 2022). Context matters.

What a High Cystatin C Signals

A result above 1.15 mg/L means the kidneys are clearing cystatin C more slowly than expected. The degree of elevation maps to CKD stage:

| Cystatin C (mg/L) | Approximate eGFRcys | CKD Stage | |---|---|---| | 0.62 to 1.15 | >60 mL/min/1.73m² | G1, G2 (normal to mildly reduced) | | 1.16 to 1.50 | 45 to 59 mL/min/1.73m² | G3a (mildly to moderately reduced) | | 1.51 to 2.00 | 30 to 44 mL/min/1.73m² | G3b (moderately to severely reduced) | | 2.01 to 3.00 | 15 to 29 mL/min/1.73m² | G4 (severely reduced) | | >3.00 | <15 mL/min/1.73m² | G5 (kidney failure) |

KDIGO 2012 guidelines recommend confirming a GFR category with cystatin C whenever the creatinine-based result falls in the G3a range, because misclassification at that boundary changes treatment decisions for at least six drug classes (KDIGO 2012 CKD guideline).

What a Low Cystatin C Signals

A cystatin C below 0.62 mg/L is uncommon. It can occur with high-dose corticosteroid use (steroids increase CST3 transcription), hyperthyroidism, or very high lean muscle mass. These are not signs of "excellent" kidney function. A low result should prompt your prescriber to interpret it alongside clinical context rather than assume a GFR above 120 mL/min/1.73m².

How Cystatin C Directly Changes Drug Prescribing

This is where your number has real consequences. The sections below cover the drug categories most relevant to HealthRX patients.

Metformin and GLP-1 Receptor Agonists

Metformin is renally cleared. The FDA label requires dose reduction when eGFR falls below 45 mL/min/1.73m² and mandates discontinuation at eGFR <30 mL/min/1.73m² due to lactic acidosis risk (FDA metformin prescribing information). If your creatinine-based eGFR reads 48 but your eGFRcys is 31, your prescriber must use the lower number. The American Diabetes Association Standards of Care 2024 state: "eGFR should be estimated using both serum creatinine and cystatin C when the creatinine-based estimate is uncertain" (ADA Standards of Care 2024).

GLP-1 receptor agonists such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are not renally cleared in a way that requires dose adjustment at most CKD stages. The FLOW trial (N=3,533) demonstrated that semaglutide 1.0 mg weekly reduced the composite kidney outcome by 24% versus placebo in patients with type 2 diabetes and CKD (eGFR 50 to 75 at baseline), with a hazard ratio of 0.76 (NEJM 2024, Perkovic et al.). Still, nausea-driven dehydration during GLP-1 titration can acutely raise cystatin C. Your prescriber may slow the titration schedule if your baseline cystatin C is already elevated.

SGLT2 Inhibitors

SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) lose glycemic efficacy as eGFR declines but retain cardiorenal benefit down to lower thresholds. The CREDENCE trial (N=4,401) showed canagliflozin reduced the composite kidney failure outcome by 30% in patients with eGFR as low as 30 mL/min/1.73m² (NEJM 2019, Perkovic et al.). The FDA-approved label now permits empagliflozin for CKD down to eGFR >20 mL/min/1.73m². Accurate staging with cystatin C keeps patients in the therapeutic window rather than stopping a kidney-protective drug prematurely.

Testosterone Replacement Therapy (TRT)

Testosterone itself is not renally cleared in a clinically significant way, but CKD changes TRT management in two directions. First, men with eGFR <60 mL/min/1.73m² are at higher risk for erythrocytosis because testosterone stimulates erythropoietin production in a setting where endogenous erythropoietin is already dysregulated. The Endocrine Society 2018 clinical practice guideline states: "We suggest measuring hematocrit before starting testosterone therapy and monitoring during treatment; hematocrit >54% should prompt dose reduction or cessation" (Endocrine Society TRT guideline 2018). Second, a falsely normal creatinine in a muscular TRT patient can mask an eGFRcys of 45, putting that patient at metformin or NSAID risk without anyone realizing it. Cystatin C closes that gap.

Hormone Replacement Therapy (HRT) and Peptides

Oral estradiol undergoes significant hepatic first-pass metabolism and is not renally dose-adjusted. Transdermal estradiol is preferred in women with CKD because it avoids the hepatic coagulation factor increase linked to venous thromboembolism, a risk amplified by CKD-related endothelial dysfunction. The ACOG recommends transdermal routes in patients with cardiovascular or metabolic comorbidities (ACOG Practice Bulletin 141).

Research peptides such as BPC-157 and TB-500 are not FDA-approved and lack pharmacokinetic data in CKD populations. Until safety data exist, an eGFRcys below 45 should trigger a prescriber-level pause on off-label peptide protocols.

NSAIDs, Antibiotics, and Contrast Agents

This category matters because many patients self-medicate with ibuprofen or naproxen without realizing their kidneys are already under stress. NSAIDs reduce renal prostaglandin synthesis and can drop GFR by 10 to 20 mL/min/1.73m² acutely in a patient with CKD G3. A single ibuprofen course can convert a stable G3a patient into a G3b patient overnight. The same logic applies to aminoglycoside antibiotics and iodinated contrast media. Knowing your cystatin C number in advance is the difference between a safe imaging study and acute kidney injury.

How to Lower a High Cystatin C

Reducing cystatin C means improving glomerular filtration rate. There is no supplement or food that directly lowers cystatin C without first improving kidney function. Strategies with evidence:

Blood Pressure Control

Hypertension is the second leading cause of CKD progression after diabetes. The SPRINT trial (N=9,361) showed that targeting systolic blood pressure <120 mmHg reduced the composite cardiovascular outcome by 25% and slowed CKD progression versus the <140 target (NEJM 2015, SPRINT Research Group). ACE inhibitors and ARBs reduce intraglomerular pressure independently of systemic blood pressure, making them first-line agents in proteinuric CKD per KDIGO 2024 guidelines (KDIGO 2024 CKD update).

Blood Sugar Optimization

The DCCT/EDIC study demonstrated that intensive glycemic control in type 1 diabetes reduced the risk of microalbuminuria by 39% over a median follow-up of 17 years (NEJM 1993 DCCT; long-term follow-up NEJM 2003). In type 2 diabetes, the ADA 2024 Standards of Care recommend an HbA1c target of <7.0% in most patients to minimize microvascular complications including nephropathy (ADA Standards of Care 2024).

Dietary Protein and Sodium

High dietary protein increases glomerular hyperfiltration. A protein intake of 0.8 g/kg/day is recommended for non-dialysis CKD patients per KDIGO 2024 (KDIGO 2024 CKD update). Sodium restriction below 2 g/day reduces proteinuria independently of blood pressure by decreasing the natriuretic response that drives glomerular pressure.

Weight Loss

Obesity-related glomerulopathy drives hyperfiltration, which eventually scars glomeruli and reduces GFR. In the LOOK AHEAD trial (N=5,145), intensive lifestyle intervention producing 8.6% weight loss at year 1 was associated with significantly less kidney function decline over 4 years compared to usual care (JASN 2014, Gregg et al.). GLP-1 agonists that produce 10 to 15% body weight reduction may improve eGFRcys over 12 to 18 months, though the mechanism includes both weight-dependent and weight-independent renal effects.

Smoking Cessation

Smoking independently accelerates CKD progression through oxidative endothelial damage. A meta-analysis of 17 studies found current smokers had a relative risk of 1.55 for CKD progression versus non-smokers (JASN 2003, Orth and Hallan). Cessation is the single zero-cost intervention your prescriber can recommend today.

How to Interpret a Low Cystatin C

A cystatin C result below 0.62 mg/L needs clinical triangulation, not celebration. Three scenarios explain most low results:

Corticosteroid Effect

Prednisone, dexamethasone, and other glucocorticoids upregulate CST3 gene transcription, increasing cystatin C production independent of GFR. A patient on 20 mg prednisone daily may show a cystatin C of 0.55 mg/L even with a true GFR of only 70 mL/min/1.73m². This is a false low. Prescribers should note current steroid dose on the requisition so the lab can flag the result appropriately. The impact is proportional to dose; low-dose hydrocortisone (<10 mg/day) used in adrenal support protocols has a smaller effect than high-dose immunosuppression.

Hyperthyroidism

Free T3 increases glomerular blood flow and also increases cystatin C production at the cellular level. Both effects can artificially suppress the apparent cystatin C-to-GFR relationship. A patient presenting with a cystatin C of 0.58 mg/L alongside suppressed TSH and a free T4 above range should have thyroid disease treated before kidney function is re-evaluated.

High Lean Body Mass in Absence of Steroid Use

In well-trained athletes who are not using exogenous steroids, cystatin C can run near the lower boundary of normal (0.60 to 0.68 mg/L) because high muscle mass correlates with higher metabolic rate and mildly elevated GFR through physiological hyperfiltration. This is not pathological, but the prescriber should confirm with 24-hour urine creatinine clearance if there is any doubt.

When to Retest Cystatin C

Testing frequency depends on your CKD stage and whether your drug regimen is changing. KDIGO 2024 recommends:

• G1, G2 with no proteinuria: once per year
• G3a, G3b: every 6 months
• G4: every 3 months
• Any new drug addition that is renally cleared: retest at 4 to 6 weeks post-initiation

Patients starting a GLP-1 agonist, SGLT2 inhibitor, or TRT protocol at HealthRX receive a cystatin C panel at baseline, at 12 weeks, and then annually if values are stable. This schedule catches the small acute GFR dip sometimes seen in the first 4 weeks of SGLT2 inhibitor therapy (an expected hemodynamic effect, not nephrotoxicity) before a prescriber over-reacts and stops a kidney-protective drug.

Cystatin C vs. Creatinine: Choosing the Right Marker

Neither test is always superior. The table below summarizes the clinical situations where each marker is preferred.

| Situation | Preferred Marker | |---|---| | Muscular patient (bodybuilder, TRT user) | Cystatin C | | Sarcopenic elderly patient | Cystatin C | | Acute kidney injury monitoring (daily changes) | Creatinine (faster turnaround, cheaper) | | GFR near 60 mL/min/1.73m² (staging uncertainty) | Both (combined CKD-EPI 2021) | | Screening in general population | Creatinine (cost-effective first step) | | Pre-contrast CT or MRI decision | Cystatin C if creatinine is borderline | | Drug dosing confirmation in G3 CKD | Both |

The 2022 NKF-ASN Task Force concluded: "We recommend reporting eGFR using both creatinine and cystatin C when eGFR confirmation is needed for clinical decisions" (NKF/ASN Task Force, JASN 2022).

Cystatin C and Cardiovascular Risk

Kidney function and cardiovascular risk are tightly linked. A cystatin C above 1.0 mg/L, even within some labs' normal ranges, predicts cardiovascular mortality independently of traditional risk factors. The Cardiovascular Health Study (N=4,663) found that each 0.1 mg/L increase in cystatin C above 0.9 mg/L was associated with a 10% increase in all-cause mortality over 9.4 years of follow-up (NEJM 2005, Shlipak et al.). This means your cystatin C result informs statin dosing, antihypertensive targets, and aspirin decisions, not just your kidney drug clearance.

The American Heart Association's 2023 Chronic Coronary Disease guideline now lists cystatin C as an optional but informative biomarker for refining cardiovascular risk in patients with intermediate 10-year Pooled Cohort Equation scores (AHA/ACC 2023 Chronic Coronary Disease guideline).

Practical Checklist Before Your Next Lab Draw

Getting an accurate cystatin C result requires a few preparation steps that labs do not always communicate:

1. Avoid high-dose biotin (vitamin B7) supplementation for 48 hours before the draw. Biotin at doses above 5 mg/day interferes with immunoassay-based cystatin C measurements, potentially producing false-low results. The FDA issued an advisory on biotin interference with immunoassays in 2017 (FDA biotin interference safety communication 2017).
2. Inform the ordering provider of any corticosteroid use, including topical or inhaled formulations at high doses.
3. Disclose current thyroid status. If you are mid-titration on levothyroxine, wait until TSH is stable before using cystatin C to make dosing decisions.
4. No fasting is required. Cystatin C is not affected by food intake, unlike lipid panels.
5. The draw can happen at any time of day. Diurnal variation in cystatin C is less than 5%.